Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Research & Development: 2009-2025

Historic Research & Development for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $99.2 million.

  • Cytokinetics' Research & Development rose 17.28% to $99.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $405.3 million, marking a year-over-year increase of 22.52%. This contributed to the annual value of $339.4 million for FY2024, which is 2.81% up from last year.
  • Latest data reveals that Cytokinetics reported Research & Development of $99.2 million as of Q3 2025, which was down 11.84% from $112.6 million recorded in Q2 2025.
  • Cytokinetics' Research & Development's 5-year high stood at $112.6 million during Q2 2025, with a 5-year trough of $31.6 million in Q1 2021.
  • Moreover, its 3-year median value for Research & Development was $84.6 million (2024), whereas its average is $89.2 million.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 100.13% in 2021, then decreased by 4.32% in 2024.
  • Cytokinetics' Research & Development (Quarterly) stood at $43.5 million in 2021, then spiked by 72.46% to $75.0 million in 2022, then grew by 13.27% to $85.0 million in 2023, then rose by 10.18% to $93.6 million in 2024, then climbed by 17.28% to $99.2 million in 2025.
  • Its Research & Development was $99.2 million in Q3 2025, compared to $112.6 million in Q2 2025 and $99.8 million in Q1 2025.